|
The UCL Institute of Ophthalmology is an institute within the Faculty of Brain Sciences of University College London (UCL) and is based in London, United Kingdom. The Institute conducts research and post-graduate teaching in the area of ophthalmology (the anatomy, physiology and diseases of the eye). The Institute has a staff of around 200, including around 45 principal investigators, and cooperates closely with Moorfields Eye Hospital, which it is located adjacent to and with which it is a partner in the NIHR Biomedical Research Centre for Ophthalmology.〔(【引用サイトリンク】title=Research )〕〔(【引用サイトリンク】title=The Moorfields Eye Hospital/UCL Institute of Ophthalmology National Institute for Health Research Biomedical Research Centre )〕 Together with Moorfields Eye Hospital, the Institute is the oldest and largest centre for ophthalmic treatment, teaching and research in Europe.〔(【引用サイトリンク】title=Europe’s largest academic health science partnership created in London )〕 ==History== The Institute of Ophthalmology was officially opened in November 1948 as an ophthalmology training facility specialised in fundamental research.〔(【引用サイトリンク】title=History of the UCL Institute of Ophthalmology )〕 During the 1980s and 1990s the Institute moved in a phased manner from its original location in Judd Street to its present site in Bath Street adjacent to Moorfields Eye Hospital.〔 The Institute merged with University College London in 1995, becoming the UCL Institute of Ophthalmology. Between 1995 and 2002 the Institute expanded following the award of £8.8 million from the Wellcome Trust and eye-research charity Fight for Sight and £6.5 million from the pharmaceutical company GlaxoSmithKline. In April 2008 the results of the world's first successful gene transplant for blindness trial, carried out by a team at the Institute and Moorfields Eye Hospital, were published. In April 2009, the Institute entered into a collaboration and license agreement with the pharmaceutical company Pfizer focused on gaining understanding into how to develop stem cell-based therapies for age-related macular degeneration. In the same month, details were published of the world's first stell cell based procedure for age-related macular degeneration, developed by researchers at the Institute and Moorfields Eye Hospital. In September 2010 the Institute entered into a three-year agreement with the pharmaceutical company AstraZeneca to collaborate on the identification of new treatments for diabetic retinopathy using the regenerative capacity of stem cells. In August 2011 the Institute and Moorfields Eye Hospital were jointly awarded a Biomedical Research Centre for Ophthalmology by the National Institute of Health Research, supported by the award of £26.5 million over five years. In September 2011 a joint team from the Institute and Moorfields Eye Hospital received approval from the UK Medicines and Healthcare products Regulatory Agency to conduct a human embryonic stem cell therapy trial on patients with the incurable eye disease Stargardt. This was the first human stem cell therapy trial to receive approval from regulators in any European country.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「UCL Institute of Ophthalmology」の詳細全文を読む スポンサード リンク
|